AxoGen, which belongs to the Zacks Medical - Instruments industry, posted revenues of $31.04 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 8.33%. This compares to year-ago revenues of $24.26 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.